{"id":584542,"date":"2025-08-28T00:00:00","date_gmt":"2025-08-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0048-2025-biopharma-myasthenia-gravis-treatment-algorithms-claims-data-analysis-us-2025\/"},"modified":"2026-06-24T11:16:50","modified_gmt":"2026-06-24T11:16:50","slug":"algocg0048-2025-biopharma-myasthenia-gravis-treatment-algorithms-claims-data-analysis-us-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0048-2025-biopharma-myasthenia-gravis-treatment-algorithms-claims-data-analysis-us-2025\/","title":{"rendered":"Myasthenia Gravis | Treatment Algorithms: Claims Data Analysis | US | 2025"},"content":{"rendered":"<p>Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is characterized by muscle weakness and fatigue. Acetylcholinesterase inhibitors (e.g., pyridostigmine), corticosteroids (e.g., prednisone), and short- and long-term immunosuppressants (e.g., mycophenolate mofetil, azathioprine) are the most prescribed agents to manage MG symptoms. Since the launch of eculizumab (Alexion \/ AstraZeneca\u2019s Soliris) in 2017, a new wave of MG therapies with unique mechanisms of action are starting to affect the treatment landscape. The FDA approved efgartigimod (Argenx\u2019s Vyvgart) in 2021 and its subcutaneous version in 2023, ravulizumab (Alexion \/ AstraZeneca\u2019s Ultomiris) in 2022, and rozanolixizumab (UCB\u2019s Rystiggo) and zilucoplan (UCB\u2019s Zilbrysq) in 2023. As MG treatment continues to evolve, this report analyzes real-world claims data to uncover prescribing trends.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MG patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MG patients?<\/li>\n<li>How have the new MG therapies been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of MG patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of MG patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Key drugs: <\/strong>Soliris, Vyvgart, Ultomiris, Rystiggo, Zilbrysq, pyridostigmine<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul>\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product <\/strong><strong>enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-584542","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/584542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=584542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}